Finance

Lists
Why is BVS up 3.04%?
Dive Deeper
BVS:NASDAQ
Bioventus Inc
$13.90
+3.04%
(+0.41) 1D
Oct 20, 10:54:18 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BVS...
Open
$13.64
High
$13.96
Low
$13.60
Mkt. cap
1.13B
Avg. vol.
422.52K
Volume
41.42K
52-wk high
$15.89
52-wk low
$6.47
Beta
0.64
Shares outstanding
68.30M
No. of employees
950
Open
$13.64
High
$13.96
Low
$13.60
Mkt. cap
1.13B
Avg. vol.
422.52K
Volume
41.42K
52-wk high
$15.89
52-wk low
$6.47
Beta
0.64
Shares outstanding
68.30M
No. of employees
950
News stories
From web sources and news partners
About Bioventus Inc
CEO-
Employees950
Founded2011
Headquarters-
SectorMedical device
Websitebioventus.com
Analyst ratings
Based on 4 analysts giving stock ratings to BVS in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for BVS in the last 3 months.
Highest
Current $13.90
$19.00 (+36.69%)
Average
$17.50 (+25.90%)
Lowest
$15.00 (+7.91%)
Analyst
Recommendation
Action
Price target
Projected
Date
Unknown Analyst
Cantor Fitzgerald
Buy
Reiterated
$15.00
+7.9%
08/17/2026
Caitlin Roberts
Canaccord Genuity
Buy
Maintained
$19.00
+36.7%
08/17/2026
William Plovanic
Canaccord Genuity
Buy
Maintained
$19.00
+36.7%
08/17/2026
Chase Knickerbocker
Craig-Hallum
Buy
Reiterated
$18.00
+29.5%
08/06/2026
Michael Petusky
Barrington
Buy
Maintained
$18.00
+29.5%
08/06/2026
Lawrence Solow
CJS Securities
Buy
Initiated
$14.00
+0.7%
03/27/2026
Next call in 14 days
Tue, Nov 3, 3:30 PM
Fiscal period
Q3 2026
- / $0.16
Revenue / Est. (USD)
- / 149.52M
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
138.65M
157.90M
132.09M
153.21M
Cost of goods sold
44.42M
49.12M
41.32M
47.54M
Cost of revenue
44.42M
49.12M
41.32M
47.54M
Research and development expenses
2.92M
3.01M
2.47M
3.17M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
78.64M
82.76M
78.31M
82.72M
Operating expense
82.96M
87.06M
81.88M
86.93M
Total operating expenses
127.39M
136.18M
123.20M
134.47M
Operating income
11.26M
21.72M
8.89M
18.73M
Other non operating income
-79.00K
-2.01M
427.00K
-
EBT including unusual items
4.67M
14.14M
4.52M
15.31M
EBT excluding unusual items
5.01M
16.38M
4.99M
14.92M
Income tax expense
664.00K
-3.18M
571.00K
-20.90M
Effective tax rate
14.22%
-22.45%
12.64%
-136.51%
Other operating expenses
-
-
-
-
Net income
3.16M
14.76M
3.11M
33.44M
Net profit margin
2.28%
9.34%
2.36%
21.83%
Earnings per share
0.15
0.24
0.15
0.22
Interest and investment income
-
-
-
-
Interest expense
-6.18M
-5.31M
-4.33M
-4.07M
Net interest expenses
-6.18M
-5.31M
-4.33M
-4.07M
Depreciation and amortization charges
1.40M
1.30M
1.11M
1.04M
EBITDA
22.67M
27.05M
20.09M
29.68M
Gain or loss from assets sale
-1.00K
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps